Journal of Hematology & Oncology | Full text | G-CSF/anti-G-CSF antibody complexes drive the potent
Administration of recombinant G-CSF following cytoreductive therapy enhances the recovery of myeloid cells, minimizing the risk of opportunistic infection. Free G-CSF, however, is expensive, exhibits a short half-life, and has poor biological activity in ...